{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-051235","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.970827+00:00","generated_at":"2026-06-05T06:25:01.223966+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Catalyst Pharma reports record 2023 revenue of $398.2M (+85.9% YoY); non-GAAP EPS $1.96","bullets":["Q4 2023 total revenue $110.6M (+82% YoY); full-year GAAP net income $71.4M ($0.63 diluted).","Non-GAAP net income $223.2M ($1.96 diluted) vs. $113.9M ($1.02) in 2022, up 96%.","FIRDAPSE net revenue $258.4M (+20.8%); FYCOMPA contributed $138.1M since acquisition.","AGAMREE FDA approval for Duchenne MD; commercial launch on track for Q1 2024.","FY2024 total revenue guidance $455M-$475M, implying ~14-19% growth vs. 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-051235","json":"https://secwatch.observer/filing/0001193125-24-051235.json","markdown":"https://secwatch.observer/filing/0001193125-24-051235.md","text":"https://secwatch.observer/filing/0001193125-24-051235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524051235/0001193125-24-051235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524051235/d776053d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:25:01.223966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}